A Study on the Use of Phase Transition Lysozyme-Loaded Minocycline Hydrochloride in the Local Treatment of Chronic Periodontitis

Abstract

Periodontitis is the most important oral disease causing human tooth loss. Although supragingival and subgingival scaling is the main strategy of periodontitis clinical treatments, drug treatment has an indispensable auxiliary role to some degree. Periodontitis medical treatment is divided into systemically administered treatments and local periodontally administered treatments. Compared with systemic administration, local administration can increase local drug concentrations, reduce dosages, and prolong action times while also improving patient compliance and avoiding possible adverse effects due to systemic administration responses. However, some studies show that minocycline ointment, a clinical local drug commonly used in periodontal pockets, has an unstable release rate; 80% of the drug is usually released within 2–3 days after pocket placement. This release is not conducive to controlling periodontal infection and may hinder the periodontal tissue repair and regeneration. Therefore, choosing a suitable carrier for minocycline hydrochloride is necessary to control its local release in periodontal tissue. Phase transition lysozyme (PTL) has been widely used in many studies and the development of macromolecular carrier material, and we selected PTL as the carrier for minocycline hydrochloride drugs because of its good biocompatibility, good drug-carrying capacity, and stable release. Due to its release characteristics and simple preparation, PTL is a promising carrier material.

Efficacy of Minocycline Hydrochloride Ointment with Metronidazole in the Treatment of Chronic Periodontitis and its Impact on Periodontal Microecology

“…investigations have demonstrated minocycline hydrochloride's antibacterial, antiinflammatory, and anti-fibrinolytic qualities, providing noteworthy efficacy in periodontitis management [8,9] . In contrast, metronidazole serves as an antimicrobial therapy, effectively inhibiting periodontal pathogens and alleviating the symptoms of chronic periodontitis [10] .…”

Minocycline hydrochloride ointment combined with Vitapex paste is effective for middle-aged and elderly patients with combined periodontal-endodontic lesions

“…It is a type of periodontal sustained-release local drug, with the main component of minocycline hydrochloride, which has the advantages of broad antibacterial spectrum and few drug-resistant bacteria [5]. It can alleviate various symptoms such as periodontitis and pulpitis caused by Porphyromonas gingivalis, Prevotella intermedia, Prevotella melaninogenicus, Ekeng corrosive bacteria, Fusobacterium nucleatum and Actinobacillus [6,7]. However, MHO may bring relatively serious side effects, including gastrointestinal symptoms, gastrointestinal diseases and dizziness [8].…”